Feasibility was assessed through several endpoints, including the proportion of eligible patients, patient compliance, patient acceptability of additional research biopsies, and the ability to assess change in tumor Ki67 (marker of proliferation) and cleaved caspase 3 (CC3, marker of apoptosis). The gene discussed is MKI67; the disease is neoplasm.